Lifeboat Foundation

Today Loremasters we explore some of hyper technology of the Necrons – the World Engine, Celestial Orrery & the Dolmen Gates.

Masters of Material Technology

The Necrons are the masters of Material technology, and their technological feats may seem magical to lesser races. Their technological masters, Crypteks, can manipulate matter at a fundamental level and wield such arcane concepts as phase-gates, subatomic infusion, and temporal looping. Several Necron super-weapons such as the World Engine and Celestial Orrery have galaxy-devastating capabilities. However it is Living Metal, or Necrodermis, which equips nearly all Necron technology. These billion-strong swarns of nano–Scarabs crawl under the skin of Necrons at a cellular level, allowing for self-repair and regeneration. Also, on particularly rare occasions, a super heavy Necron device called a Necron Pylon is seen. It is feared for its extreme power and ability to appear anywhere on the battlefield.

Researchers at the University at Albany’s RNA Institute have demonstrated a new approach to DNA nanostructure assembly that does not require magnesium. The method improves the biostability of the structures, making them more useful and reliable in a range of applications. The work appears in the journal Small this month.

When we think of DNA, the first association that comes to mind is likely genetics—the double helix structure within cells that houses an organism’s blueprint for growth and reproduction. A rapidly evolving area of DNA research is that of DNA nanostructures—synthetic molecules made up of the same building blocks as the DNA found in living cells, which are being engineered to solve critical challenges in applications ranging from medical diagnostics and drug delivery to materials science and data storage.

“In this work, we assembled DNA nanostructures without using magnesium, which is typically used in this process but comes with challenges that ultimately reduce the utility of the nanostructures that are produced,” said Arun Richard Chandrasekaran, corresponding author of the study and senior research scientist at the RNA Institute.

Northwestern Medicine investigators have developed a novel nanoparticle treatment for glioblastoma, according to a study published in Nature Communications.

Glioblastoma, the most common type of primary brain cancer, is one of the most complex, deadly and treatment-resistant cancers, according to the National Brain Tumor Society. The five-year survival rate for glioblastoma patients hovers near 7% and has remained unchanged for decades.

Previous Northwestern Medicine research has shown that glioblastoma tumors accumulate large numbers of immunosuppressive tumor-associated myeloid cells (TAMCs), which impairs the immune system’s ability to fight the tumor and reduces the effectiveness of radiation and chemotherapy.

Carbon nanotubes (CNTs) are considered ideal electrochemical energy storage materials due to their high electrical conductivity, large theoretical surface area, and good chemical stability.

However, CNTs tend to aggregate due to strong van der Waals forces, which reduces their electrochemically active area. This problem is even worse for single-walled carbon nanotubes (SWNTs) due to their high length-to-diameter ratio.

Recently, a joint research team led by Dr. Wang Xiao from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences, Dr. Zhu Sheng from Shanxi University, and Prof. Li Yan from Peking University has encapsulated polyoxometalate guest molecules within SWNTs (with a diameter of approximately 1.4 nm) to enhance the electrochemical energy storage of CNTs.

The fact that our immune systems capture and destroy nanoparticles and the drugs they carry has been a problem in the field of nanomedicine for some time. But, in the fight against cancer, researchers are now attempting to exploit this problem to their advantage.

Researchers around the world are seeking to identify techniques that use nanoparticles in the treatment of disease. Such particles are about 100 nanometers—one thousandth of a millimeter—in diameter, and within them researchers are inserting large numbers of even smaller drug molecules.

Optimism for this approach in the treatment of various forms of cancer has been particularly great.

Prostate cancer is the most common non-skin cancer in men worldwide. According to international estimates about one in six men will get prostate cancer during their lifetime and worldwide, over 375,000 patients will die from it each year. Tumor resistance to current therapies plays an essential role in this and new approaches are therefore urgently needed.

Now an international research team from the University of Bern, Inselspital Bern and the University of Connecticut has identified a previously unknown weak spot in prostate cancer cells. This weak spot is possibly also present in other cancer cells. The study was led by Mark Rubin from the Department for Biomedical Research (DBMR) and Center for Precision Medicine (BCPM) at the University of Bern and Inselspital Bern, and Rahul Kanadia from the Department of Physiology and Neurobiology and the Institute for Systems Genomics at the University of Connecticut. The research results have been published in the journal Molecular Cell.

“We took a closer look at a certain molecular machine called the spliceosome,” explains Anke Augspach, lead author of the study and researcher from the Department for BioMedical Research (DBMR). “It plays an important role in the translation of genes into proteins. In this process, the spliceosome separates parts of the gene that are not needed for the production of the protein and fuses the other parts.”

Almost as soon as there were super-resolution microscopes, scientists pointed them towards molecular motors called kinesins. These proteins, powered by the molecular fuel ATP, drive crucial processes including cell division, cell signalling and intracellular transport by shuttling cargo along protein highways called microtubules. Researchers have long wanted to understand how these motors work, but to visualize them, scientists have had to slow them down or isolate them in simplified, in vitro systems.

Now, in papers published concurrently in Science, two teams working independently have used a super-resolution tool called MINFLUX to study the motor in near-real time at physiologically relevant concentrations of ATP. The first paper, led by MINFLUX’s inventor, Stefan Hell, who has a joint appointment at the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen and the MPI for Medical Research in Heidelberg, both in Germany, used a new instrument design to track the protein in 3D, revealing details about its motion¹. The second, led by biophysicist Jonas Ries at the European Molecular Biology Laboratory in Heidelberg, showed for the first time that MINFLUX is capable of tracking kinesin even amid the bustle of living cells².

“This technology requires a lot of different things to work, and it’s fun to see all of these things coming together,” says Michelle Digman, a biomedical engineer at the University of California, Irvine, who develops imaging strategies but was not involved in either study. “It seemed like a proof of concept to show that they’re able to track kinesin very precisely. And when you have the live cell system, that’s even more spectacular.”

https://www.youtube.com/@ForesightInstitute/videos

Is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.

From molecular nanotechnology, to brain-computer interfaces, space exploration, cryptocommerce, and AI, Foresight gathers leading minds to advance research and accelerate progress toward flourishing futures.

Former Google engineer and esteemed futurist Ray Kurzweil has made another bold prediction: Immortality is within reach for humans by 2030, thanks to the help of nanorobots. You read that right — humans could potentially live forever, according to Kurzweil.

Don’t Miss: Why Jason Calacanis and Other Silicon Valley Elites Are Betting On This Startups Vision For Re-Uniting American Families

Kurzweil, who has a track record of accurate predictions such as foreseeing a computer beating humans in chess by 2000, shared his prediction in a recent YouTube series by tech vlogger Adagio. The 75-year-old computer scientist believes that advancements in genetics, robotics and nanotechnology will allow tiny robots to run through veins, repairing any damage and keeping people alive indefinitely.